Clinical trials: CINV
Colorectal Cancer
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
The object of this study is to evaluate the superiority of aprepitant therapy with a 5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a 5HT3-receptor antagonist and dexamethasone for…
- Trial name
- NCT01344304
- Testing
- Aprepitant / Fosaprepitant
- Where
- 27 sites in Japan
- Volunteers
- 413 people
- Sponsor
- Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-Induced Nausea and Vomiting (CINV)
Safety Study of Repeat Doses of SUSTOL in Adults
This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL®…
- Trial name
- NCT05434663
- Testing
- SUSTOL
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life and may affect patients' treatment decisions.
- Trial name
- NCT04085393
- Testing
- GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic…
- Trial name
- NCT01031498
- Testing
- Ondansetron, Palonosetron
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms
Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
To evaluate the safety of Fosaprepitant Dimeglumine Injection for the prevention of nausea and vomiting caused by tumor chemotherapy drugs, analyze the characteristics of the applicable population and clinical medication of…
- Trial name
- COSEFDIP (NCT05755659)
- Testing
- Fosaprepitant Dimeglumine for Injection
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Xijing Hospital
Nausea and Vomiting
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical…
- Trial name
- TSEPHCC (NCT05690802)
- Testing
- Palonosetron hydrochloride capsules
- Where
- China
- Volunteers
- 1,060 people
- Sponsor
- Xijing Hospital
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Gynecological Tumor, Ovarian Cancer
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor. Paclitaxel-carboplatin (TC) is the most widely used regimen for gynecologic malignancies, yet chemotherapy-induced…
- Conditions
- Gynecological Tumor, Ovarian Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT06007586
- Testing
- Aprepitant Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Chemotherapy Induced Nausea and Vomiting
Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients
The aim of present study is to evaluate if the addition of Aprepitant to multiple doses of palonosetron IV enhances the efficacy of multiple doses of palonosetron IV alone, in preventing CINV in AML or High risk MDS patient…
- Trial name
- NCT02205164
- Testing
- Palonosetron + Aprepitant, Palonosetron
- Where
- 11 sites in Italy
- Volunteers
- 134 people
- Sponsor
- Associazione Salentina Angela Serra
Chemotherapy-induced Nausea and Vomiting
Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV
Nausea and vomiting caused by chemotherapy are considered by patients as the main side effects of cancer treatment, which affect the quality of treatment and life.At present, NCCN guidelines have recommended three or four drug…
- Trial name
- NCT05805800
- Testing
- 5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Xingchen Peng
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC).
- Trial name
- NCT00337727
- Testing
- aprepitant, Comparator: ondansetron, Comparator: dexamethasone
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Neoplasm
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
This phase II trial studies how well netupitant and palonosetron hydrochloride work in preventing chemotherapy induced nausea and vomiting in patients with cancer undergoing BEAM conditioning regimen before stem cell transplant.
- Trial name
- NCT03097588
- Testing
- Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- OHSU Knight Cancer Institute
Oncology, Breast Cancer
Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy
This study explores whether a commonly used medication called Pantoprazole can help prevent delayed nausea and vomiting from chemotherapy for early breast cancer.
- Conditions
- Oncology, Breast Cancer, Chemotherapy-induced Nausea and Vomiting
- Trial name
- PantoCIN (NCT03948477)
- Testing
- Pantoprazole 40mg
- Where
- 10 sites in New Zealand
- Volunteers
- 160 people
- Sponsor
- University of Auckland, New Zealand
Chemotherapy-induced Nausea and Vomiting (CINV)
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
- Trial name
- NCT00952341
- Testing
- aprepitant, dexamethasone, granisetron
- Volunteers
- 421 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
This study evaluates the possibility to reduce the total dose of dexamethasone, when administered with NEPA, to prevent chemotherapy-induced nausea and vomiting (CINV) in Non-Small Cell Lung Cancer (NSCLC) patients receiving a…
- Trial name
- LUNG-NEPA (NCT04201769)
- Testing
- Netupitant/Palonosetron, Dexamethasone
- Where
- 26 sites in Italy
- Volunteers
- 261 people
- Sponsor
- Consorzio Oncotech
Chemotherapy-induced Nausea and Vomiting
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Trial name
- NCT00273468
- Testing
- Granisetron
- Volunteers
- 630 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea
HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study
HR20013 is a newly approved medicine in China to prevent nausea and vomiting from anticancer treatment. This prospective, observational, multicenter real-world study will enroll about 3,000 patients receiving this medicine as…
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea, Vomiting, Neoplasms
- Trial name
- HR20013-RWS (NCT07874308)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Sun Yat-sen University